Baseline characteristics and 30-day safety outcomes
| Characteristics | Patients (n=1140) | Therapy | |||
| BMS (n=375) | SES (n=714) | Angioplasty (n=51) | P value* | ||
| Age, mean (SD) | 62.4 (9.2) | 68.1 (6.3) | 59.0 (8.9) | 66.6 (9.5) | <0.0001 |
| Sex (male) | 833 (73.1) | 274 (73.1) | 520 (72.8) | 39 (76.5) | 0.8518 |
| Hypertension | 878 (77.0) | 313 (83.5) | 525 (73.5) | 40 (78.4) | 0.0010 |
| Diabetes mellitus | 242 (21.2) | 73 (19.5) | 154 (21.6) | 15 (29.4) | 0.2481 |
| Hyperlipidemia | 367 (32.2) | 122 (32.5) | 228 (31.9) | 17 (33.3) | 0.9644 |
| Smoking | 550 (48.3) | 167 (44.5) | 346 (48.5) | 37 (72.6) | 0.0008 |
| Coronary heart disease | 225 (19.7) | 103 (27.5) | 115 (16.1) | 7 (13.7) | <0.0001 |
| Alcohol | 68 (6.0) | 25 (6.7) | 39 (5.5) | 4 (7.8) | 0.6152 |
| Atrial fibrillation | 44 (3.9) | 18 (4.8) | 22 (3.1) | 4 (7.8) | 0.1200 |
| Postoperative anticoagulation | 85 (7.5) | 23 (6.1) | 48 (6.7) | 14 (27.5) | <0.0001 |
| Qualifying artery | |||||
| ICA | 195 (17.1) | 43 (11.5) | 138 (19.3) | 14 (27.5) | <0.0001 |
| MCA | 312 (27.4) | 83 (22.1) | 208 (29.1) | 21 (41.2) | |
| VA | 352 (30.9) | 226 (60.3) | 125 (17.5) | 1 (2.0) | |
| BA | 281 (24.7) | 23 (6.1) | 243 (34.0) | 15 (29.4) | |
| Mori classification | |||||
| A | 578 (50.7) | 303 (80.8) | 239 (33.5) | 36 (70.6) | <0.0001 |
| B | 387 (34.0) | 9 (2.52) | 366 (50.2) | 12 (22.2) | |
| C | 175 (15.4) | 30 (8.4) | 143 (19.62) | 2 (3.7) | |
| Baseline mRS≥3 | 23 (2.0) | 7 (1.9) | 16 (2.2) | 0 | <0.0001 |
| Mean stenosis pre procedure, mean (SD), % | 86.3 (5.0) | 86.9 (4.7) | 85.9 (5.2) | 86.4 (4.8) | <0.0001 |
| Volume of study centre | |||||
| High | 774 (67.9) | 313 (83.5) | 411 (57.6) | 50 (98.0) | <0.0001 |
| Middle | 294 (25.8) | 56 (14.9) | 237 (33.2) | 1 (2.0) | |
| Low | 72 (6.3) | 6 (1.6) | 66 (9.2) | 0 | |
| Primary outcomes | 111 (9.7) | 47 (12.5) | 62 (8.7) | 2 (3.9) | 0.0450 |
| Secondary outcomes | |||||
| Ischaemic | 53 (4.7) | 23 (6.1) | 28 (3.9) | 2 (3.9) | 0.2495 |
| Perforator occlusion | 41 (3.6) | 17 (4.5) | 22 (3.1) | 2 (3.9) | 0.4696 |
| In-stent thrombosis | 8 (0.7) | 4 (1.1) | 4 (0.6) | 0 | 0.5267 |
| Other | 4 (0.4) | 2 (0.5) | 2 (0.3) | 0 | 0.6753 |
| Haemorrhagic | 58 (5.1) | 24 (6.4) | 34 (4.8) | 0 | 0.1207 |
| SAH | 28 (2.5) | 15 (4.0) | 13 (1.8) | 0 | 0.0446 |
| SICH | 30 (2.6) | 9 (2.4) | 21 (2.9) | 0 | 0.4223 |
| Death | 12 (1.1) | 5 (1.3) | 7 (1.0) | 0 | 0.6499 |
Data are reported as No. (%) unless otherwise indicated.
*the null hypothesis was that characteristics were not different among three subgroups, the same hereinafter.
BA, Basilar artery; BMS, balloon-mounted stent; ICA, internal carotid artery; MCA, middle cerebral artery; mRS, modified Rankin Scale; SAH, subarachnoid haemorrhage; SES, self-expanding stent; SICH, symptomatic intracranial/intraparenchymal haemorrhage; VA, vertebral artery.